50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Acute Lymphocytic Leukemia - Therapy, Excluding Transplantation Poster III

Monday, December 8, 2008: 5:30 PM-7:30 PM

Hall A (Moscone Center)

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

Elias Jabbour¹, Susan O'Brien¹^*, Deborah A. Thomas¹^*, Stefan Faderl, MD¹, Charles Asa Koller, MD¹, Samuel Dara, Coordinator, Clinical, Studies²^*, Rebecca Garris, Data, Analyst²^*, Jorge Cortes, MD¹, Hagop M Kantarjian³ and Farhad Ravandi¹^*

¹M.D. Anderson Cancer Center, Houston, TX
²Leukemia, UTMD Anderson Cancer Center, Houston, TX
³The University of Texas M. D. Anderson Cancer Center, Houston, TX

2920

Dasatinib (Sprycel®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Positive ALL: Results of the First 22 Patients Included in the EWALL-Ph-01 Trial (on Behalf of the European Working Group on Adult ALL (EWALL))

Philippe Rousselot¹^*, Jean-Michel Cayuela²^*, Christian Recher³^*, Thibaut Leguay⁴^*, Célia Salanoubat⁵^*, Francis Witz⁶^*, Magda Alexis⁷^*, Maud Janvier⁸^*, Mathilde Hunault⁹^*, Philippe Agape¹⁰^*, Christian Berthou¹¹^*, Eric Jourdan¹²^*, José Fernandes¹³^*, Laurent Sutton¹⁴^*, Anne Banos¹⁵^*, Oumedaly Reman¹⁶^*, Bruno Lioure, MD¹⁷^*, Nicola Gökbuget¹⁸^*, Dieter Hoelzer, MD, PhD¹⁹, André Delannoy²⁰^*, Renato Bassan²¹^*, Jose-Maria Ribera²²^*, Sebastian Giebel²³^*, Sandrine Hayette²⁴^*, Oliver Ottmann²⁵ and Hervé Dombret²⁶

¹Centre André Mignot, Versaille, France
²Hôpital Saint-Louis, AP-HP, Paris, France
³CHU Toulouse, Toulouse, France
⁴Hôpital du Haut Levèque, Pessac, France
⁵Hôpital de Créteil, Créteil, France
⁶CHU de Nancy, Nancy, France
⁷CHU la Source, Orléans, France
⁸Centre Huguenin, Saint-Cloud, France
⁹CHU d'Angers, Angers, France
¹⁰CH F Guyon, La Réunion, France
¹¹CHU Brest, Brest, France
¹²CHU de Nimes, Nimes, France
¹³CH Valenciennes, Valenciennes, France
¹⁴CH Argenteuil, Argenteuil, France
¹⁵CH Bayonne, Bayonne, France
¹⁶CHU Caen, Caen, France
¹⁷Département d'Hématologie et d'Oncologie, CHU Hautepierre, Strasbourg, France
¹⁸Klinikum der J.W.Goethe Universität, Frankfurt, Germany
¹⁹J.W. Goethe University Hospital, Frankfurt/M, Germany
²⁰Hôpital de Jolimont, Haine Saint-Paul, Belgium
²¹Ospedali Riuniti di Bergamo, Italy
²²Hospital Germans Trials i Pujol, Badalona, Spain
²³Medical University of Silesia, Katowice, Poland
²⁴Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
²⁵Goethe University, Frankfurt, Germany
²⁶Hopital Saint Louis AP-HP, Paris, France

2921

Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Farhad Ravandi, MBBS¹, Deborah Thomas, MD², Hagop Kantarjian, MD²^*, Stefan Faderl, MD²^*, Charles Koller, MD²^*, Samuel Dara, MD²^*, Rebecca Garris, BS²^*, Partow Kebriaei, MD³^*, Gautam Borthakur, MD²^*, William Wierda, MD, PhD²^*, Jan Burger, MD²^*, Jorge Cortes, MD²^* and Susan O'Brien, MD²^*

¹Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Cellualr Therapy and Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX

2922

Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL

Enzi Jiang, MD, PhD¹^*, Min Yu, MD, PhD¹^*, Yao-Te Hsieh¹^*, Brian DeLaTorre¹^*, Asha Kadavallore¹^*, Carlton Scharman¹^*, Eugene Park¹^*, Allen S. Yang, MD, PhD², Markus Muschen, MD¹, John Groffen, PhD¹^*, Nora Heisterkamp, PhD¹^* and Yong-Mi Kim, MD¹

¹Pediatrics, CHLA-USC, Los Angeles, CA
²Jane Anne Nohl Division of Hematology, University of Southern California, Los Angeles, CA

2923

Histone Deacetylase Inhibitors Induce FPGS mRNA Expression and Intracellular Accumulation of Long-Chain Methotrexate Polyglutamates in Childhood Acute Lymphoblastic Leukemia: Implications for Combination Therapy

Guy J Leclerc, Ph.D.¹^*, Caihong Mou, M.D.²^*, Gilles M Leclerc, Ph.D.¹^*, Abdul M Mian, Ph.D.²^* and Julio C Barredo, M.D.¹

¹Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL
²UM Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

2924

Acquired Bcr-Abl Kinase Domain Mutations Are Not Responsible for Persistence of Dasatinib-Refractory Disease in Murine Ph+ ALL

Nidal Boulos, PhD¹^*, Charles J. Sherr, MD, PhD²^* and Richard T Williams, MD, PhD³

¹Oncology, St Jude Children's Research Hospital, Memphis, TN
²Howard Hughes Medical Institute and Genetics and Tumor Cell Biology, St Jude Children's Research Hospital, Memphis, TN
³Oncology, St. Jude Children's Research Hospital, Memphis, TN

2925

Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia

Nobuko Hijiya, MD¹^*, Paul S. Gaynon, MD², Manuel Fernandez³^*, Lewis B. Silverman, MD⁴, Blythe Thomson, MD⁵, Roland Chu⁶^*, Todd Cooper, DO⁷, Richard Kadota, MD⁸, Michael Rytting, M.D.⁹, Peter G. Steinherz, MD¹⁰, Violet Shen¹¹^*, Sima Jeha, MD¹², Elly Barry, MD¹³^* and William L. Carroll, MD¹⁴

¹Children's Memorial Hospital, Chicago, IL
²Out-Patient Towers, Childrens Hosp. of Los Angeles, Los Angeles, CA
³Genzyme Corporation, San Antonio, TX
⁴Pediatric Oncology, Dana-Farber Cancer Inst., Boston, MA
⁵Children's Hosp. & Regional Med. Ctr., Seattle, WA
⁶Department of Pediatrics, Wayne University, Detroit,, MI
⁷University of Alabama, Birmingham, AL
⁸Children's Hosp. of San Diego, San Diego, CA
⁹Pediatric Hematology-Oncology, M.D. Anderson Cancer Center, Houston, TX
¹⁰Memorial Sloan-Kettering Cancer Center, New York, NY
¹¹CHOC Pediatric Subspecialty Faculty, Orange,, CA
¹²St. Jude Children's Rsch. Hosp., Memphis, TN
¹³Genzyme Corporation, Boston, MA
¹⁴New York University Cancer Institute, New York, NY

2926

Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180-035

Richard A. Larson, MD¹, Oliver G. Ottmann, MD², Neil P. Shah, MD, PhD³, Michael B. Lilly, MD⁴, Josy M. Reiffers⁵^*, Aude Charbonnier⁶^*, Gerhard Ehninger, MD⁷, M. Brigid Bradley-Garelik⁸^*, Chao Zhu⁸^* and Giovanni Martinelli, MD⁹

¹University of Chicago, Chicago, IL
²Hematology and Oncology, Universitatsklinik Frankfurt, Frankfurt, Germany
³San Francisco School of Medicine, University of California, San Francisco, CA
⁴University of California Irvine Medical Center, Irvine, CA
⁵CRLCC Institut Bergonié, Bordeaux, France
⁶Institut Paoli Calmettes, Marseille, France
⁷Medizinische Klinik, Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Germany
⁸Bristol-Myers Squibb, Wallingford, CT
⁹Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy

2927

Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells

David Teachey, MD¹^*, Cecilia Sheen¹^*, Alix Eden Seif, MD, MPH², Valerie I. Brown, MD, PhD¹^* and Stephan A. Grupp, MD, PhD¹^*

¹Children's Hospital of Philadelphia, Philadelphia, PA
²Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA

2928

Peripheral Neuropathy Profile of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo^®), a Nanoparticle Vincristine Formulation, in Adult Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s Lymphoma (NHL)

Biao Lu, PhD^*, Anne E Hagey, MD^*, Feng Zhou, MS^* and Steven R. Deitcher, MD

Hana Biosciences, South San Francisco, CA

2929

Stapled Peptides: Leveraging the BH3 α-Helix to Create a New Class of Drugs to Treat Hematological Malignancies

Rosana Kapeller¹^*, Jiawen Han¹^*, Kaiming Sun¹^*, Pranoti Gangurde¹^*, Nori Kawahata¹^*, Matt Iadanza¹^*, Vincent Guerlevais¹^*, Jim Horstick¹^*, Justin Noehre¹^*, Allen Annis¹^*, Larry Licklider¹^*, Huw M. Nash¹^*, Andrew Kung²^* and Tomi K. Sawyer¹^*

¹AILERON Therapeutics, Inc., Cambridge, MA
²Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

2930

Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes Injection (VSLI, Marqibo^TM) Plus Dexamethasone in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Deborah A. Thomas, MD¹, Hagop M Kantarjian, MD¹^*, Wendy Stock, MD², Leonard Heffner, MD³, Sue Hirabayashi, MBA⁴^*, Biao Lu, PhD⁵^*, Steven R. Deitcher, MD⁵ and Susan O'Brien, MD¹^*

¹Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
²Section Hem./Onc., University of Chicago, Chicago, IL
³Emory Univ. Sch. of Med., The Emory Clinic, Atlanta, GA
⁴Hana Biosciences Inc., South San Francisco, CA
⁵Hana Biosciences, South San Francisco, CA

2931

Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Deborah A. Thomas, MD¹, Hagop M Kantarjian², Jorge Cortes, MD³, Farhad Ravandi, MBBS⁴, Stefan Faderl, MD³, Dan Jones, MD, PhD⁵, Laurie A. Letvak, MD⁶, Partow Kebriaei, MD⁷, Richard E Champlin, MD⁸^* and Susan O'Brien, M.D.⁹

¹Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
²The University of Texas M. D. Anderson Cancer Center, Houston, TX
³M.D. Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
⁵UT M.D. Anderson Cancer Ctr., Houston, TX
⁶Novartis Oncology, East Hanover, NJ
⁷Dept. of Stem Cell Transplantation, UTMD Anderson Cancer Center, Houston, TX
⁸Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX
⁹Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH